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B
efore 1979, kinases were only 
thought to stick phosphates on two 
of the twenty amino acids: serine 
and threonine. But then Tony Hunter 
discovered that tyrosine could also be 
phosphorylated (1, 2), thereby uncovering 
an entirely new mechanism of protein 
regulation in cells. Since then, Hunter 
has worked on all sorts of protein phos-
phorylation events and the kinases that 
deliver them. Indeed, he has been instru-
mental in deducing the 
human kinome (3, 4).
Protein phosphoryla-
tion events have an im-
pact on practically every 
cellular pathway to some 
degree, but the main focus 
of Hunter’s work has been 
their particular relevance 
in cancer (5). Hunter, who 
is a fellow of the Royal 
Society and member of the National Acad-
emy of Sciences, is director of the Cancer 
Center and American Cancer Society pro-
fessor at the Salk Institute in San Diego.
In a recent interview, Hunter recounted 
the tale of his tyrosine phosphorylation 
discovery. And it’s a tale with an important 
lesson: never dismiss an anomalous result—
even if you’re using out-of-date reagents!
EARLY FOCUS
How did you get started in science?
My father was a surgeon in the UK Nation-
al Health Service. He got me interested in 
biology fairly early. Then, when I went to 
public school at the age of 13, I was pushed 
up a class, and within the fi  rst week a deci-
sion had to be made whether I should take 
classics or science as my major subject.
My father and the headmaster had a 
conversation, the result of which was that 
I was pretty much specialized in science 
from then on.
That was very young for such a decision. 
Were you happy with it?
I could have been happy either way, I 
expect. Clearly, I was good at science. I was 
not so good at math, which was an issue 
and still is. But science was easy, so I 
never really questioned the decision.
Did you ever think about following in 
your father’s footsteps?
I did, but he strongly discouraged me. He 
felt that the National Health Service leveled 
all doctors, so that the talented ones really 
weren’t given the due they deserved.
I don’t think I would have been a very 
good doctor. I don’t have the people skills 
or the necessary compassion.
So you chose biology when you went off 
to Cambridge?
I read natural sciences at Cambridge and 
specialized in biochemistry for my fi  nal 
year. But I didn’t go to university straight 
after my A levels. I was still only 16 and I 
didn’t feel ready. Most people going to 
university are 18, and that’s the drinking 
age, so I think it makes sense to go when 
you’re 18 to enjoy it!
You then stayed on at Cambridge?
Someone in the biochemistry department 
suggested that I apply for an MRC student-
ship to do graduate work. I thought, “Well, 
it seems like a reasonable thing to do, and 
the path of least resistance.”
I opted to join Asher Korner’s lab, which 
was the one lab in the department doing 
anything resembling molecular biology at 
the time. He actually left in the middle of my 
Ph.D. to take up the chair in biology in 
Sussex, but I decided not to move with him.
Was that rather disrupting?
Not at all. He never spent much time talk-
ing to us. He let us do what we wanted. 
We each had our own projects that we 
developed, so it didn’t make a lot of dif-
ference. Nevertheless, he was very impor-
tant in creating a great lab environment 
and recruiting the best graduate students. 
Four out of the nine students who were 
there at the same time as me are now 
fellows of the Royal Society. It was really 
a very eminent group of young scientists.
What was it about molecular biology 
that appealed to you?
It was the mid-1960s, and the genetic 
code was just being solved. The fi  rst protein 
structures were just beginning to emerge. 
The structure of DNA had been solved. 
It seemed like if you really wanted to 
understand how cells or organisms worked, 
you’d have to understand how the mole-
cules worked inside the cells.
It was a really exciting time, because we 
were right there at the cutting edge, even as 
students. In the department in the center of 
town, we were very much the poor cousins 
to the Laboratory of Molecular Biology 
(LMB) up the road, where all the high pro-
fi  le molecular science was going on. But 
we went up there for seminars, and people 
from there, like Fred Sanger, Sydney 
Brenner, and Max Perutz, would come and 
lecture to us, which was fantastic.
UK TO USA TO UK…
If it was going so well, what made you 
head off to the States?
After my Ph.D., I stayed on as a college 
fellow for four years and was planning on 
staying longer, but I married Pippa Mar-
rack, who was a grad student at the LMB. 
She was a couple of years behind me and 
wanted to come to UCSD to do a postdoc 
with Dick Dutton.
Obviously, we had to stick together, so 
Alan Munro, who had done a one-year 
sabbatical here at the Salk Institute sug-
gested that I work with Walter Eckhart, a 
new faculty member at Salk who worked 
on polyoma virus, a small DNA tumor 
virus. I thought, “Sounds interesting,” 
and I met Eckhart at a meeting in London, 
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and he agreed to take me into his lab. So in 
1971, Pippa and I came out to San Diego.
I teamed up with a postdoc in Walter 
Eckhart’s lab, and we produced a bunch of 
papers together, setting up polyoma virus 
DNA synthesis as an in vitro model for 
DNA replication. That worked pretty well. 
But during this time, Pippa and I split up, and 
I decided I would go back to Cambridge.
Then six months later, back in Cam-
bridge, we burned the lab down. The ori-
gin of the fi  re is still obscure, but it was 
probably caused by ether. It was pretty 
bad. We lost most of our stuff, but luckily 
the liquid nitrogen canister containing all 
our precious biologicals survived.
Phew!
Yeah. We were homeless, but luckily a 
new university building had just been 
built right opposite the LMB, and we were 
offered space there on an empty fl  oor. 
We actually had a functioning lab again in 
less than six weeks.
Max Perutz, director of the LMB, 
generously offered us dining rights in the 
LMB canteen—the famous canteen where 
everyone was supposed to sit at tables that 
did not have any of your lab mates, in order 
to promote scientifi  c discussion. As a 
result, we hooked up with a group work-
ing on tobacco mosaic virus and had a 
very fruitful collaboration.
During this time, I applied for a couple 
of faculty positions in the UK but had no 
luck. So I wrote to Walter Eckhart, who had 
offered me a position before I left the Salk. 
He told me it was still open, so I moved 
back to San Diego in February, 1975.
…AND BACK
A few years later, you discovered that 
tyrosines could be phosphorylated. 
What led up to that?
When I got back, I had begun working on 
polyoma virus again and by this time we 
knew that a protein called middle T antigen, 
which gets expressed immediately after 
the virus infects cells, could by itself 
transform fi  broblasts. We wanted to know 
how but were at a bit of a loss.
A postdoc then joined my lab and 
started trying to identify the transforming 
protein for a different tumor virus: Rous 
sarcoma virus. We were beaten to the 
punch by Ray Erikson’s group, who 
identifi  ed the Src protein. They also dis-
covered that Src was a kinase.
That led us to test whether the polyoma 
virus middle T antigen was also a kinase. 
And it was. Erikson had reported that Src 
phosphorylates threonine. So I started 
routine hydrolysis experiments to identify 
the amino acid target of the polyoma kinase. 
One evening I ran a hydrolyzed sample of 
labeled middle T antigen from polyoma-
infected cells together with markers for 
phosphoserine and phosphothreonine—
the only known phosphoamino acids at the 
time. The next day, it was clear that the 
target amino acid was neither phospho-
serine nor phosphothreonine.
My biochemistry training came in use-
ful, because I knew that there was a third 
hydroxyl amino acid, tyrosine, that could 
potentially be phosphorylated. I crudely 
synthesized some phosphotyrosine, ran it 
against the polyoma sample, and found 
that indeed tyrosine was the polyoma 
kinase target.
To run the thin layer plates, I had been 
using an old bottle of pH 1.9 buffer. Then, 
rather foolishly, I made up some fresh 
buffer to repeat the experiment. To my 
horror, I discovered that phosphotyrosine 
and phosphothreonine migrated together! 
I spent some time aging the buffer, and it 
turns out that this causes its pH to drop 
slightly, allowing the two phosphoamino 
acids to run separately.
I later ran a sample of the Src kinase 
product as a control, and much to my 
amazement, this turned out also to phos-
phorylate tyrosine. Erikson had been 
misled by of the comigration of phospho-
tyrosine and phosphothreonine when he 
reported that Src is a threonine kinase.
Ah, he should have 
been using old buffer!
Yes! When the story 
broke, the word spread 
incredibly fast. I spoke 
about it in December 
1979 in Basel, and soon 
everyone knew about it 
and started testing their 
favorite transforming 
proteins. Within a year, 
we knew that tyrosine 
phosphorylation was important for normal 
cells, and within three or four years, it was 
clear this was a major regulatory system. 
Then in the early ’80s, the fi  rst mutations 
in tyrosine kinases and its link with cancer 
began to be reported.
Since then, you’ve worked on all sorts 
of kinases. What’s the next big question 
in kinase biology?
Several published studies say that there are 
thousands of different phosphorylation 
events in a typical cell. So, the key ques-
tions are, What do they all do? And how 
many of them are noise? For some proteins, 
we know they’re phosphorylated under par-
ticular conditions, but it’s proved diffi  cult to 
fi  gure out how that changes their function. 
Also, for proteins with multiple sites of 
phosphorylation, do different combinations 
of phosphates mean different things?
Then, of course, there’s the other side 
of the coin: the phosphatases. There are 
over 500 kinases and maybe 150 or so 
phosphatases. So there’s a lot of interest 
in trying to build networks of phosphor-
ylation events—the systems biology ap-
proach. I think that’s certainly going to 
be a very important area.
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A recent study from Hunter’s lab reveals how 
the action of kinases affects cell movement 
(colored lines) in a model of cancer.
“Rather 
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